The Genomics Core provides consultation and state-of-the-art genomic technologies to KCI investigators. Core scientists interact with KCI researchers to design experiments, generate preliminary data, write methodologies, and generate and analyze experimental data. The Core supports research investigating genetic factors: a) responsible for cancer susceptibility, b) involved in neoplastic initiation and progression, and c) affecting cancer treatment. Existing Core technologies include: 1) nucleic acid isolation (Qiagen TissueLyser, AutoPure and EZ1 Advanced); 2) DNA sequencing (Applied Biosystems 3730 and 3100); 3) genotyping (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System); 4) expression analysis (Applied Biosystems 7900, lllumina iScan, and Affymetrix GeneChip System);and 5) Next Generation Sequencing (lllumina Genome Analyzer NX with paired-end module).
The Genomics Core supports research investigating genetic factors responsible for cancer susceptibility involved in neoplastic initiation and progression, and affecting cancer treatment using high-throughput technologies in a cost-effective manner.
|Hastert, T A; de Oliveira Otto, M C; Lê-Scherban, F et al. (2018) Association of plasma phospholipid polyunsaturated and trans fatty acids with body mass index: results from the Multi-Ethnic Study of Atherosclerosis. Int J Obes (Lond) 42:433-440|
|Bock, Cathryn H; Jay, Allison M; Dyson, Gregory et al. (2018) The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women's Health Initiative observational study. Breast Cancer Res Treat 167:741-749|
|Mittal, Sandeep; Klinger, Neil V; Michelhaugh, Sharon K et al. (2018) Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies. J Neurosurg 128:414-421|
|Park, Hyo K; Schildkraut, Joellen M; Alberg, Anthony J et al. (2018) Benign gynecologic conditions are associated with ovarian cancer risk in African-American women: a case-control study. Cancer Causes Control 29:1081-1091|
|Heyza, Joshua; Lei, Wen; Watza, Donovan et al. (2018) Identification and characterization of synthetic viability with ERCC1 deficiency in response to interstrand crosslinks in lung cancer. Clin Cancer Res :|
|Bonomi, Robin; Popov, Vadim; Laws, Maxwell T et al. (2018) Molecular Imaging of Sirtuin1 Expression-Activity in Rat Brain Using Positron-Emission Tomography-Magnetic-Resonance Imaging with [18F]-2-Fluorobenzoylaminohexanoicanilide. J Med Chem 61:7116-7130|
|Paximadis, Peter; Beebe-Dimmer, Jennifer L; George, Julie et al. (2018) Comparing Treatment Strategies for Stage I Small-cell lung Cancer. Clin Lung Cancer 19:e559-e565|
|Su, Yongwei; Li, Xinyu; Ma, Jun et al. (2018) Targeting PI3K, mTOR, ERK, and Bcl-2 signaling network shows superior antileukemic activity against AML ex vivo. Biochem Pharmacol 148:13-26|
|Teslow, Emily A; Bao, Bin; Dyson, Greg et al. (2018) Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells. Mol Oncol 12:1138-1152|
|Modi, Dipenkumar; Al-Kadhimi, Zaid; Chen, Wei et al. (2018) A phase II study of tacrolimus and thymoglobulin as graft-versus-host-disease prophylaxis in related donor allogeneic hematopoietic cell transplantation. Am J Hematol 93:E96-E98|
Showing the most recent 10 out of 826 publications